Diagnosing and Managing Polypoidal Choroidal Vasculopathy

Evidence-based strategies for diagnosis and therapeutic decision-making.

By Giulia Gregori, MD, Jay Chhablani, MD

Dual-Pathway Gene Therapy for Geographic Atrophy

An approach currently being investigated would combine neuroprotection and complement modulation.

By Thomas A. Ciulla, MD, MBA

The Evolving TKI Pipeline

Several agents are being investigated for durability and clinical potential in retinal vascular disease.

By Simrat K. Sodhi, MSc, MB BChir (Cantab), David S. Boyer, MD

The Therapeutic Pipeline for Geographic Atrophy

Reviewing the next wave of clinical-stage therapies in development for GA.

By Benedict Uzorka, BS, Jessica D. Randolph, MD

When Adnexal Lymphoma Mimics Retinal Disease

A case highlights how mucosal lymphoma can initially be misdiagnosed as uveitis and chorioretinopathy, underscoring the need for broad diagnostic consideration.

By Zack Oakey, MD

COMO and CAPRI Trials Evaluate Duravyu in DME

Retina Conversations: Veeral S. Sheth, MD, MBA, FACS, FASRS, reviews the design and goals of the phase 3 trials of EyePoint’s Duravyu in DME.

By Veeral S. Sheth, MD, MBA, FACS

Innovative Therapies in the nAMD Pipeline: What’s Coming Next?

A review of next-generation biologics and gene therapies designed to extend durability and reduce treatment burden in neovascular age-related macular degeneration.

By Naveen Karthik, MD, Sharon Fekrat, MD, FASRS

The Excitement of Clinical Trials

Upfront: The March/April issue has a focus on age-related macular degeneration.

By Diana V. Do, MD

Can Photobiomodulation Regulate Dry AMD?

Controversies in Care: Evaluating whether evidence for PBM reflects a true treatment effect or arises from natural variability.

By Tiago Rassi, MD, Daniel M. Berinstein, MD, Michael Colucciello, MD

Why Uveitis Fellowship Deserves a Second Look

Uveitis Corner: Survey data and specialist insights challenge long-standing misconceptions about uveitis training, surgery, and compensation.

By John A. Gonzales, MD , Jessica Shantha, MD, Sruthi Arepalli, MD, et al.

Coding Wet and Dry AMD

Coding Q&A: Key distinctions in ICD-10 coding for wet and dry AMD to prevent denials and delays.

By Elizabeth Cifers, MBA, MSW, CHC, CPC

Clinical Trial Update March 2026

Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.

Time Management in Retina Practices

Practice Management Strategies: Managing What Matters When the Day Won’t Cooperate

By Elizabeth Cifers, MBA, MSW, CHC, CPC

Axpaxli Could Transform Wet AMD Care

Retina Conversations: Ocular Therapeutics head Pravin U. Dugel, MD, explains SOL-1 trial results and how Axpaxli could reshape wet AMD treatment.

By Pravin U. Dugel, MD

Video: Pegcetacoplan Data Show Increasing Benefit Over 5 Years

At the 2026 Macula Society meeting, Dilsher S. Dhoot, MD, discussed GALE extension results demonstrating progressive tissue preservation in geographic atrophy.

By Dilsher S. Dhoot, MD

Video: 3-Year Data Show Vision Gains With Optogenetic Therapy for RP

Long-term results presented at the Macula Society meeting highlight durable BCVA improvements with Nanoscope Therapeutics’s MCO-010.

By Christine Nichols Kay, MD

Retinal Disease Prevalence Study Reveals Gaps

A meta-analysis quantified prevalence and revealed disparities by race, sex, and geography. 

Managing DME When Anti-VEGF Response Is Limited

Retina Minute: Drs. Kuppermann and Singer discuss ERYLDEX data on the potential benefit of dexamethasone implant in DME patients with inadequate anti-VEGF response.

By Baruch D. Kuppermann, MD, PhD, Michael A. Singer, MD

Revisiting Steroids in DME

In this month’s Retina Minute, Christopher D. Riemann, MD, discusses data from the NEW DAY trial that supports earlier use of fluocinolone acetonide in DME.

By Michael A. Singer, MD, Christopher D. Riemann, MD